These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27539365)

  • 1. Effect of design specifications in dose-finding trials for combination therapies in oncology.
    Hirakawa A; Sato H; Gosho M
    Pharm Stat; 2016 Nov; 15(6):531-540. PubMed ID: 27539365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying a maximum tolerated contour in two-dimensional dose finding.
    Wages NA
    Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
    Shimamura F; Hamada C; Matsui S; Hirakawa A
    J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
    Hirakawa A; Wages NA; Sato H; Matsui S
    Stat Med; 2015 Oct; 34(24):3194-213. PubMed ID: 25974405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
    Kakurai Y; Hirakawa A; Hamada C
    J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical designs for Phase I combination studies in oncology.
    Wages NA; Ivanova A; Marchenko O
    J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specifications of a continual reassessment method design for phase I trials of combined drugs.
    Wages NA; Conaway MR
    Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II adaptive design for drug combination oncology trials.
    Wages NA; Conaway MR
    Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
    Mozgunov P; Jaki T; Paoletti X
    J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
    Yada S; Hamada C
    Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.